Back to all studies
CompletedNCT01149655

Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) for schizophrenia

This study is completed in the United States, in India, in Malaysia, .... It is testing Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) for schizophrenia.

SchizophreniaDrugFrom 13 Years to 17 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Oral Aripiprazole may be useful for adolescents experiencing schizophrenia.

What would participation involve?

Participants may receive Oral Aripiprazole, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in India, in Malaysia, and in the Philippines.

Who is it mainly for?

This study appears to be mainly for adolescents with schizophrenia. Because it involves minors, a parent or guardian may need to be involved.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 2011
Recruitment status
Completed
Enrollment listed in the registry
252
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, India, Malaysia, ...
Age range
From 13 Years to 17 Years
Official registry ID
NCT01149655
Official title
A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT01149655. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

India · 11 sites
  • Study Site
    Vijayawada, Andhra Pradesh
    Site status: Not listed — confirm with the team
  • Study Site
    Visakhapatnam, Andhra Pradesh
    Site status: Not listed — confirm with the team
  • Study Site
    Raipur, Chhattisgarh
    Site status: Not listed — confirm with the team
  • Study Site
    Maninagar, Ahmedabad, Gujarat
    Site status: Not listed — confirm with the team
  • Study Site
    Aurangabad, Maharashtra
    Site status: Not listed — confirm with the team
  • Study Site
    Wardha, Maharashtra
    Site status: Not listed — confirm with the team
  • Study Site
    Chennai, Tamil Nadu
    Site status: Not listed — confirm with the team
  • Study Site
    Madurai, Tamil Nadu
    Site status: Not listed — confirm with the team
  • Study Site
    Lucknow, Uttar Pradesh
    Site status: Not listed — confirm with the team
  • Study Site
    Varanasi, Uttar Pradesh
    Site status: Not listed — confirm with the team
  • Study Site
    Guntur
    Site status: Not listed — confirm with the team
Malaysia · 4 sites
  • Study Site
    Kuala Lumpur, Kuala Lumpur
    Site status: Not listed — confirm with the team
  • Study Site
    Ipoh, Perak
    Site status: Not listed — confirm with the team
  • Study Site
    Batu Caves, Selangor
    Site status: Not listed — confirm with the team
  • Study Site
    Johor Bahru
    Site status: Not listed — confirm with the team
Philippines · 5 sites
  • Study Site
    Dasmariñas, Cavite
    Site status: Not listed — confirm with the team
  • Study Site
    Bajada, Davao City
    Site status: Not listed — confirm with the team
  • Study Site
    Manila, National Capital Region
    Site status: Not listed — confirm with the team
  • Study Site
    Iloilo City
    Site status: Not listed — confirm with the team
  • Study Site
    Mandaluyong
    Site status: Not listed — confirm with the team
Romania · 5 sites
  • Study Site
    Cluj-Napoca, Cluj
    Site status: Not listed — confirm with the team
  • Study Site
    Craiova, Dolj
    Site status: Not listed — confirm with the team
  • Study Site
    Timișoara, Timiș County
    Site status: Not listed — confirm with the team
  • Study Site
    Bucharest
    Site status: Not listed — confirm with the team
  • Study Site
    Iași
    Site status: Not listed — confirm with the team
Russia · 16 sites
  • Study Site
    Arkhangelsk
    Site status: Not listed — confirm with the team
  • Study Site
    Kazan'
    Site status: Not listed — confirm with the team
  • Study Site
    Lipetsk
    Site status: Not listed — confirm with the team
  • Study Site
    Moscow
    Site status: Not listed — confirm with the team
  • Study Site
    Moscow
    Site status: Not listed — confirm with the team
  • Study Site
    Nizhny Novgorod
    Site status: Not listed — confirm with the team
  • Study Site
    Novosibirsk
    Site status: Not listed — confirm with the team
  • Study Site
    Orenburg
    Site status: Not listed — confirm with the team
  • Study Site
    Petrozavodsk
    Site status: Not listed — confirm with the team
  • Study Site
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Study Site
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Study Site
    Saratov
    Site status: Not listed — confirm with the team
  • Study Site
    Tomsk
    Site status: Not listed — confirm with the team
  • Study Site
    Tonnelnyi Township
    Site status: Not listed — confirm with the team
  • Study Site
    Yaroslavl
    Site status: Not listed — confirm with the team
  • Study Site
    Yekaterinburg
    Site status: Not listed — confirm with the team
Taiwan · 3 sites
  • Study Site
    Kaohsiung County
    Site status: Not listed — confirm with the team
  • Study Site
    Taipei
    Site status: Not listed — confirm with the team
  • Study Site
    Taoyuan County
    Site status: Not listed — confirm with the team
United States · 8 sites
  • Study Site
    Downy, California
    Site status: Not listed — confirm with the team
  • Study Site
    Glendale, California
    Site status: Not listed — confirm with the team
  • Study Site
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Study Site
    Miami Springs, Florida
    Site status: Not listed — confirm with the team
  • Study Site
    Atlanta, Georgia
    Site status: Not listed — confirm with the team
  • Study Site
    Bloomfield Hills, Michigan
    Site status: Not listed — confirm with the team
  • Study Site
    Chapel Hill, North Carolina
    Site status: Not listed — confirm with the team
  • Study Site
    Bothell, Washington
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Aripiprazole. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 13 Years to 17 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., which appears to be a pharmaceutical company. Sponsor website: https://www.otsuka.co.jp/en/. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me